SLRN Profile
Acelyrin, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying, acquiring, and expediting the development of transformative therapies for serious medical conditions. Based in Agoura Hills, California, Acelyrin focuses on leveraging its innovative drug development capabilities to bring forward therapies with significant potential to address unmet medical needs.
The company's flagship candidate, izokibep, is a small protein therapeutic designed to inhibit interleukin-17A (IL-17A) with high potency. Izokibep is currently undergoing Phase 3 clinical trials for the treatment of hidradenitis suppurativa, psoriatic arthritis, and uveitis, and is also being tested in Phase 2 trials for axial spondyloarthritis. This approach highlights Acelyrin's commitment to advancing targeted therapies that can potentially offer substantial benefits over existing treatments.
In addition to izokibep, Acelyrin is developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R). Lonigutamab is currently in Phase 1 trials for the treatment of thyroid eye disease, reflecting the company's focus on addressing complex conditions with novel therapeutic approaches. Acelyrin is also advancing SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical development for chronic urticaria, further broadening the company’s pipeline.
Founded in 2020, Acelyrin, Inc. is at the forefront of biopharmaceutical innovation, harnessing cutting-edge research to develop therapies that could redefine treatment paradigms. The company’s robust pipeline, including both clinical and preclinical candidates, underscores its strategic focus on high-impact therapeutic areas. By accelerating the development of its promising drug candidates, Acelyrin aims to deliver significant advancements in patient care and address some of the most challenging medical conditions.
|
